Remove Initial Public Offering Remove Mergers and Acquisitions Remove Public Trading
article thumbnail

MergersCorp Expands Services to SPAC Companies Amid Growing Market Demand

MergersCorp M&A International

In a significant move to capitalize on the burgeoning Special Purpose Acquisition Company (SPAC) market, MergersCorp has announced the launch of specialized services tailored specifically for SPACs. This innovative approach has attracted substantial interest from investors, entrepreneurially minded companies, and financial institutions alike.

article thumbnail

Investment Banking – Meaning, Functions and More

Razorpay

Investment banking is a branch of banking that organizes and enables large, complex financial transactions for businesses, like mergers, IPOs or underwriting. Investment Banking Services Initial Public Offering (IPO) When a privately-owned business wants to become a publicly traded company, it goes through an IPO , or Initial Public Offering.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Why Aren’t More Tire Dealerships Going Public?

Focus Investment Banking

The benefits of going public are significant. First, there’s the ability to raise substantial capital by issuing shares to the public in an initial public offering (IPO), as well as secondary offerings. For more information, contact him at michael.mcgregor@focusbankers.com.

article thumbnail

Transfer Traps: Considerations for Dual-Class Companies Contemplating M&A Transactions

Cooley M&A

The rise of founder-led, venture capital-backed companies in recent years has coincided with a surge of companies implementing dual-class share structures in connection with their initial public offerings. Voting agreements in public M&A transactions. Stockholder litigation. As always, ambiguity begets litigation.

M&A 59
article thumbnail

Cooley’s 2022 Life Sciences M&A Year in Review

Cooley M&A

But it wasn’t all carve outs and concerned investors – even with the headwinds in the industry and beyond, there were still several traditional public M&A deals involving biotechnology or medical device companies, as large pharmaceutical companies continued to have cash to deploy for acquisitions. Let’s dig in.

M&A 40
article thumbnail

Cooley’s 2022 Tech M&A Year in Review

Cooley M&A

The year started off with a bang, with mega-deals such as Microsoft’s pending $69 billion acquisition of Activision Blizzard, Elon Musk’s $44 billion acquisition of Twitter and Broadcom’s pending $61 billion acquisition of VMware inked in quick succession. Tech M&A in 2022 was a tale of two halves.

M&A 52
article thumbnail

Cooley’s 2024 Life Sciences M&A Year in Review: M&A Slims Down in 2024, but Will Appetites Grow in 2025?

Cooley M&A

billion acquisition of Alpine Immune; by contrast, there were eight US biotech acquisitions exceeding $5 billion in 2023. 2024 saw companies focusing on internal research and development, innovative partnerships, and targeted bolt-on asset acquisitions to bolster their pipelines. from 2023. [1]

M&A 64